全文获取类型
收费全文 | 1604篇 |
免费 | 132篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 30篇 |
妇产科学 | 7篇 |
基础医学 | 194篇 |
口腔科学 | 34篇 |
临床医学 | 129篇 |
内科学 | 468篇 |
皮肤病学 | 20篇 |
神经病学 | 47篇 |
特种医学 | 52篇 |
外科学 | 269篇 |
综合类 | 77篇 |
预防医学 | 90篇 |
眼科学 | 44篇 |
药学 | 77篇 |
中国医学 | 25篇 |
肿瘤学 | 161篇 |
出版年
2023年 | 14篇 |
2022年 | 20篇 |
2021年 | 40篇 |
2020年 | 33篇 |
2019年 | 28篇 |
2018年 | 54篇 |
2017年 | 30篇 |
2016年 | 30篇 |
2015年 | 49篇 |
2014年 | 49篇 |
2013年 | 49篇 |
2012年 | 90篇 |
2011年 | 118篇 |
2010年 | 55篇 |
2009年 | 52篇 |
2008年 | 82篇 |
2007年 | 96篇 |
2006年 | 101篇 |
2005年 | 73篇 |
2004年 | 98篇 |
2003年 | 100篇 |
2002年 | 58篇 |
2001年 | 55篇 |
2000年 | 49篇 |
1999年 | 38篇 |
1998年 | 9篇 |
1997年 | 11篇 |
1996年 | 13篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 8篇 |
1992年 | 22篇 |
1991年 | 25篇 |
1990年 | 22篇 |
1989年 | 23篇 |
1988年 | 21篇 |
1987年 | 18篇 |
1986年 | 22篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1977年 | 8篇 |
1975年 | 2篇 |
1974年 | 5篇 |
1972年 | 7篇 |
1971年 | 7篇 |
1970年 | 3篇 |
排序方式: 共有1746条查询结果,搜索用时 31 毫秒
51.
Tomonari A Takahashi S Ooi J Tsukada N Konuma T Kato S Kasahara S Iseki T Yamaguchi T Tojo A Asano S 《European journal of haematology》2008,80(3):251-257
Cytomegalovirus (CMV) disease is one of the major infectious complications after allogeneic hematopoietic stem cell transplantation (SCT). Several studies have shown that CMV-seropositive patients have a substantial survival disadvantage after bone marrow transplantation (BMT) or peripheral blood SCT (PBSCT). Between August 1998 and February 2006, 101 adult patients underwent myeloablative cord blood transplantation (CBT) from unrelated donors at our institution. Sixteen and 85 patients were CMV-seronegative and CMV-seropositive, respectively, prior to CBT. Outcomes of CBT were compared between CMV-seronegative and CMV-seropositive patients. The cumulative incidences of neutrophil engraftment at 60 d after CBT did not differ between CMV-seronegative and CMV-seropositive patients (100% and 94%, P = 0.09); however, the cumulative incidence of platelet engraftment at 100 d was higher in CMV-seronegative patients than CMV-seropositive patients (100% vs. 86%, P < 0.005). The cumulative incidence of CMV antigenemia at 100 d was lower in CMV-seronegative patients than CMV-seropositive patients (0% vs. 77%, P < 0.001); however, the cumulative incidences of CMV disease did not differ between CMV-seronegative and CMV-seropositive patients (0% vs. 1%, P = 0.84). The probabilities of disease-free survival at 2 yr also did not differ between CMV-seronegative and CMV-seropositive patients (92% vs. 72%, P = 0.16). The outcomes of CBT for CMV-seropositive patients as well as CMV-seronegative patients in our series were favorable. This might be due to effective antiviral therapy for CMV infection. Large-scale studies are needed to determine the impact of recipient CMV serostatus on the outcome of CBT for adults. 相似文献
52.
53.
Ooi J Iseki T Takahashi S Tomonari A Nagayama H Ishii K Ito K Sato H Takahashi T Shindo M Sekine R Ohno N Uchimaru K Nagamura F Shirafuji N Tojo A Tani K Asano S 《British journal of haematology》2002,118(1):140-143
We performed a clinical comparison of unrelated cord blood transplantation (UCBT) and unrelated bone marrow transplantation in adult acute leukaemia patients in complete remission (CR) who received the same conditioning regimen, graft-versus-host disease (GvHD) prophylaxis and supportive treatment. The incidence of acute GvHD was almost the same between the two groups, but the haematopoietic recovery was delayed and the incidence of chronic GvHD was higher in the UCBT group. The probability of 2 year disease-free survival was similar between the two groups. These results suggest that adult acute leukaemia patients in CR without a suitable donor should be considered as candidates for UCBT. 相似文献
54.
55.
Hertz JT Munishi OM Ooi EE Howe S Lim WY Chow A Morrissey AB Bartlett JA Onyango JJ Maro VP Kinabo GD Saganda W Gubler DJ Crump JA 《The American journal of tropical medicine and hygiene》2012,86(1):171-177
Consecutive febrile admissions were enrolled at two hospitals in Moshi, Tanzania. Confirmed acute Chikungunya virus (CHIKV), Dengue virus (DENV), and flavivirus infection were defined as a positive polymerase chain reaction (PCR) result. Presumptive acute DENV infection was defined as a positive anti-DENV immunoglobulin M (IgM) enzyme-linked immunsorbent assay (ELISA) result, and prior flavivirus exposure was defined as a positive anti-DENV IgG ELISA result. Among 870 participants, PCR testing was performed on 700 (80.5%). Of these, 55 (7.9%) had confirmed acute CHIKV infection, whereas no participants had confirmed acute DENV or flavivirus infection. Anti-DENV IgM serologic testing was performed for 747 (85.9%) participants, and of these 71 (9.5%) had presumptive acute DENV infection. Anti-DENV IgG serologic testing was performed for 751 (86.3%) participants, and of these 80 (10.7%) had prior flavivirus exposure. CHIKV infection was more common among infants and children than adults and adolescents (odds ratio [OR] 1.9, P = 0.026) and among HIV-infected patients with severe immunosuppression (OR 10.5, P = 0.007). CHIKV infection is an important but unrecognized cause of febrile illness in northern Tanzania. DENV or other closely related flaviviruses are likely also circulating. 相似文献
56.
57.
58.
59.
60.
Chronic kidney disease (CKD) is not only a common comorbidity among patients presenting with acute coronary syndrome (ACS), it is also an entity that portends worse short- and long-term prognosis. Differences in the pathophysiology of arterial atherosclerosis and calcification, chronic inflammation, platelet reactivity, and thrombogenicity in patients with and without CKD underpin the increased vulnerability of CKD patients with ACS to subsequent ischemic and bleeding complications. These differences, as well as the frequent exclusion of CKD patients from randomized control trials, create uncertainty regarding the benefit of invasive treatment for ACS in patients with CKD. The limited evidence from randomized trials suggests a benefit with invasive treatment in CKD patients with ACS. However, some data from registry studies suggest no benefit or even harm with invasive therapy. Thus, the optimal management of ACS in patients with CKD, in particular end-stage CKD, remains uncertain. In this article we review the characteristics of coronary artery disease in patients with CKD, the available evidence pertaining to the outcomes of CKD patients with ACS with invasive versus conservative therapy, and potential areas for reducing complications of invasive therapy in this high-risk subset of patients. 相似文献